Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Reexamination Certificate
2011-03-08
2011-03-08
Jones, D L (Department: 1618)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
C424S001110, C424S001650, C424S001810, C424S001850, C424S009100, C544S001000, C544S224000
Reexamination Certificate
active
07901667
ABSTRACT:
The present invention relates to compounds having the general formula: Y-L-BFR-X wherein BFR is a bridged fused ring system; Y is a targeting group; L is optionally present and is a linker for coupling Y to BFR; and X is halogen (e.g., radiohalogen) or a functional group for labelling.
REFERENCES:
patent: 5714342 (1998-02-01), Komoriya et al.
patent: WO 95/24218 (1995-09-01), None
patent: WO 00/43110 (2000-07-01), None
patent: WO 01/34586 (2001-05-01), None
Samnick et al., “Electrophysiological Study, Biodistribution in Mice . . . ”, Nuclear Medicine & Biology, 1998, vol. 25, pp. 323-330.
Hackenberger, et al., “General Synthesis of Unsymmetrical Norborname Scaffolds as Inducers for Hydrogen Bond Interactions in Peptides”, J. Org. Chem., 2004, 69, pp. 739-743.
Houle et al., “Imaging the 5-HT1A receptors with PET: WAY-100635 and analogues”, Nuclear Medicine and biology, vol. 27, No. 5, Jul. 2000, pp. 463-466, XP004216841, p. 465, col. 1, paragraph 4.
Wilson et al., “Derivatives of way 100635 as potential imaging agents for 5-htla receptors: syntheses, radiosyntheses, and in vitro and in vivo evaluation—A new 5-HT1A receptor ligand”, Nuclear Medicine and Biology, vol. 25, No. 8, Nov. 1998, pp. 769-776, XP004142586, p. 771; compounds 7, 8, 13.
Cliffe, “A retrospect on the discovery of way-100635 and the prospect for improved 5-HT1A receptor PET radioligands”, Nuclear Medicine and Biology, vol. 27, No. 5, Jul. 2000, pp. 441-447, XP004216838, abstract, figures 5-5; compounds 9, 13.
Zhuang, et al., “Synthesis and evaluation of 4-(2′-Methoxyphenyl)-1-02′-UN-2-Pyridinyl)-P-Iodobenzamidoethylpiperazine (P-MPPI): A new iodinated 5-HT1A Ligand”, Journal of Medicinal chemistry, American Chemical Society, vol. 37, No. 10, May 13, 1994, pp. 1406-1407, XP002027735, p. 1406: figure 1, p. 1407, col. 2, paragraph 1.
Lang et al., “Development of fluorine-18-labeled 5-HT1A antagonists” Journal of Medicinal Chemistry, May 6, 1999, vol. 42, No. 9, pp. 1576-1586, XP002421051, p. 1578; figure 1; compounds 4B, 4C.
Lang et al., “Fluoro analogs of WAY-100635 with varying pharmacokinetics properties”, Nuclear Medicine and Biology, vol. 27, No. 5, Jul. 2000, pp. 457-462, XP004216840, abstract; p. 458, col. 1; figure 1.
Zhuang et al., “Isoindol-1-one analogures of 4-(2′-methoxyphenyl)1-[2′[N-(2′ ′-pyridyl)-p-iodobenzamido]ethyl]piperazine (p-MPPI) as 5-HT1A receptor ligands”, Journal of Medicinal Chemistry, American chemical Society, vol. 41, No. 2, Jan. 15, 1998, pp. 157-166, XP002357875, abstract.
Abou-Gharbia et al., “Synthesis and Sar of Adatanserin: Novel Adamantyl Aryland Heteroarylipiperazines With Dual Serotonin 5-HT1A and 5-HT2 Activity as Potential Anxiolytic and Antidepressant Agents”, Journal of Medicinal Chemistry, American chemical Society, vol. 42, No. 25, 1999, pp. 5077-5094, XP000973607, p. 5078-p. 5079; figure 1.
Raghupathi et al., “Analogues of the 5-HT1A Serotonin antagonist 1-(2-Methoxyphenyl)-4-4-(2-Phthalimido) But Ylpiperazine with Reduced Alpha1-Adrenergic Affinity”, Journal of Medicinal Chemistry, American chemical Society, vol. 34, No. 8, 1991, pp. 2633-2638, XP000986140, compound 2K.
Orjales et al., “New (2-methoxyphenyl)piperazine derivatives as 5-HT-1A receptor ligands with reduced alpha-1-adrenergic activity. Synthesis and structure-affinity relationships”, Journal of Medicinal chemistry, American Chemical Society, vol. 8, No. 38, 1995, pp. 1273-1277, XP002074046, compounds 2A,2B,2C,2F,2G,2H,2I.
Braker et al., Radioiodination of bridgehead carbon atoms in adamantine structures, 2003, J. Label. Compd. Radiopharm, 46: S190, abstract.
Carson et al., “Evaluation of a new F-18 labelled analog of the 5-HT antagonist WAY-100635 for PET”, J. Nucl. Med, 39,1998, p. 135, abstract 553.
Hnatowich et al., “Radioactive Labelling of Antibody: A simple and efficient method”, 1983, 220, pp. 613-615.
Pelegrin et al., “Photoinnunodiagnosis with antibody-fluorescein conjugates: in vitro and in vivo preclinical studies”, Journal of Cellular Pharmacology, 1992, 3, pp. 141-145.
Achilefu et al., “Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging”, Investigative Radiology, 2000, 35(8), pp. 479-485.
Ballow et al., “Tumor labeling in vivo using cyanine-conjugated monoclonal antibodies”, Cancer Immunology and Immunotherapy, 1995, 41, pp. 157-263.
Della and Tsanaktsidis, “Synthesis of bridgehead-bridgehead substituted bicycloalkanes”, Aust. J. Chem, 1985, 38, pp. 1705-1718.
Licha et al., “New contrast agents for optical imaging: acid-cleavable conjugates of cyanine dyes and biomolecules”, In Biomedical Imaging: Reporters, Dyes, and Instrumentation, Proceeding of SPIE, 1999, 3600, pp. 29-35.
Priefer et al., “Effective synthetic routes to cubylcarbionol derivatives”, Synthesis, 2002, pp. 2671-2673.
Eaton, Phillip. E., Cubanes: Starting Materials for the Chemistry of the 1990s and the New Century, Agnew. Chem. Int. Ed. Engl., 1992, 31, 1421-1436.
Braker et al., Adsorption of radioiodine on platinum: a fast and simple column method to obtain concentrated and pure radioiodide in either water or anhydrous solvents, Appl. Radiat. Isot., 2002, 57, pp. 475-482.
Della and Tsankatsidis, “Synthesis of bridgehead-bridgehead substituted biocycloalkanes”, Aust. J. Chem., 1985, 38, pp. 1705-1718.
Priefer, et al., Effective Synthetic Routes to Cubylcarbinol Derivatives, Synthesis, 2002, pp. 2671-2673.
Bunce, “A mercury salt pathway for the degradation of carboxylic acids to alkyl halides suing halogen and mercuric oxide”, J. Org. Chem., 1972, 37, pp. 664-669.
Herscheid et al., “Synthesis of 1231-Radiopharmaceuticals with the Label in a Bridgehead Position”, 2005, J. Label. Compd. Radiopharm, 48: S54 abstract.
Herscheid Jacobus Donatus M.
Verbeek Joost
Jones D L
Mallinckrodt Inc.
LandOfFree
Bridgehead labelled compounds and methods of using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bridgehead labelled compounds and methods of using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bridgehead labelled compounds and methods of using the same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2754256